TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00181363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mamma board
Description: use of mamma board during radiotherapy
Study: NCT03310723

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face Mask preoxygenation
Description: Standard face mask preoxygenation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OptiFlow preoxygenation
Description: Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
Study: NCT04435444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Masterful supportive care
Description: Three study questionnaires:~Functional Assessment of Cancer Therapy-General\* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being\* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form\* (MSAS-SF)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention control supportive care
Description: Three study questionnaires:~Functional Assessment of Cancer Therapy-General\* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being\* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form\* (MSAS-SF)
Study: NCT03300401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microspheres
Description: Receive intravenous injection just prior to ultrasound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride Lipid Microspheres
Description: Receive intravenous injection just prior to ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Ultrasound Imaging
Description: Undergo Contrast-Enhanced Ultrasound Imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yttrium-90 (90Y)
Description: Given IV
Study: NCT03816735

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cikatridina
Description: Women are asked to insert the suppositories according to the manufacturer's protocol.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juliet Feminine Laser
Description: Women will receive the laser treatment twice during the study period.
Study: NCT01179321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early referral to Dietitian for assessment and nutrition support
Study: NCT01467141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Injected s.c. (under the skin) three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human insulin
Description: Injected s.c. (under the skin) 30 minutes before the meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isophane human insulin
Description: May be administered s.c. (under the skin) in both treatment groups thrice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isophane human insulin
Description: May be administered s.c. (under the skin) in both treatment groups thrice daily
Study: NCT02431988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Patients will undergo leukapheresis prior to pre-conditioning chemotherapy to provide the immune cells required to produce the therapeutic product.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive a standard pre-conditioning regime with cyclophosphamide 60mg/kg/day IV over 1 hour for 2 days (day-7 and day-6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25mg/m2/day IV over 15/30 minutes for 5 days (Day-5 to day-1).
Study: NCT03147404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
Study: NCT02512367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental care education program
Description: Dental care education program

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Surveillance
Description: Surveillance
Study: NCT01553773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoflavone
Description: treatments: a gel with 17-β estradiol 0.01% (n = 15) and a gel with isoflavones (genistein 4%). The gels were applied once per day. the lenght of treatment was 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: a gel with 17-β estradiol 0.01%. Once per day. The lenght of treatment was 24 weeks.
Study: NCT03090243

Intervention type: DEVICE
Intervention: Virtual colonoscopy
Description: Inserting a Foley catheter through the anus, and gas inflating of the bowel.
Study: NCT02176213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg PO x 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: low dose cyclophosphamide 50 mg PO BID x 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone 40 mg PO weekly (or 20 mg if ≥ 75 years old).
Study: NCT02145234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986089
Study: NCT02431988

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR19 T-Cells
Description: The CAR19 T-cells are to be administered on day 0 at the dose specified by the Cancer Trials Centre (CTC) at the time of registration.~Three dose cohorts are planned:~* Dose Level 1: 2x105 CAR19 T-cells/kg~* Dose Level 2: 1x106 CAR19 T-cells/kg~* Dose Level 3: 5x106 CAR19 T-cells/kg
Study: NCT01317758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03 Adjuvant
Description: Adjuvant/diluent manufactured by GlaxoSmithKline (GSK)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03 Adjuvant
Description: Adjuvant/diluent manufactured by GlaxoSmithKline (GSK)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03 Adjuvant
Description: Adjuvant/diluent manufactured by GlaxoSmithKline (GSK)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Placebo/diluent provided by sanofi pasteur

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Placebo/diluent provided by sanofi pasteur

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Placebo/diluent provided by sanofi pasteur

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sanofi H5N1 Antigen
Description: Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, administered at 3.75, 7.5, or 15mcg, with either AS03 adjuvant or PBS.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sanofi H5N1 Antigen
Description: Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, administered at 3.75, 7.5, or 15mcg, with either AS03 adjuvant or PBS.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sanofi H5N1 Antigen
Description: Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, administered at 3.75, 7.5, or 15mcg, with either AS03 adjuvant or PBS.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sanofi H5N1 Antigen
Description: Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, administered at 3.75, 7.5, or 15mcg, with either AS03 adjuvant or PBS.
Study: NCT02145234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986089
Study: NCT01317758

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sanofi H5N1 Antigen
Description: Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, administered at 3.75, 7.5, or 15mcg, with either AS03 adjuvant or PBS.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sanofi H5N1 Antigen
Description: Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, administered at 3.75, 7.5, or 15mcg, with either AS03 adjuvant or PBS.
Study: NCT03422029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-Dotatate PRRT
Description: PRRT using 177Lu-Dotatate 100-150mCi will be performed 8-weekly. A maximum of 8 cycles will be administered.~Other: Amino-Acid Solution The Amino-Acid Solution (AAS) to be used in this study, infused over 4-6 h, starting 30 min before PRRT
Study: NCT04737278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cunermuspir
Description: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:~Organic evaporated cane juice powder, hypromellose, titanium dioxide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: same non-medical ingredients and encapsulation as Intervention 1
Study: NCT03453905

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CTFEA
Description: CT scans are used to generate a finite element model of patient-specific long bones. The bone model is loaded in stance position. Load based on patient's weight and the mechanical response, including the risk of fracture, is computed.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional decision algorithm
Description: Decision on surgery vs follow-up will be based on expert opinion and Mirels' score
Study: NCT00837915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets
Study: NCT00217425

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: A - CHOP: 15 mg/kg IV infusion once every 21 days for 6-8 cycles. Bevacizumab is to be administered prior to CHOP therapy. Continuous bevacizumab: 15 mg/kg IV infusion once every 21 days.~Initial dose should be infused over 90 minutes. If no adverse reactions occur, the second dose should be administered over 60 minutes. Again, if no adverse reactions occur, the third and subsequent doses should be administered over 30 minutes. If infusion-related adverse reactions occur, subsequent infusions should be administered over the shortest period that is well-tolerated. Infusions should be run in via a volumetric infusion device. Do NOT administer as an IV push or bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: IV infusion per institutional guidelines.
Study: NCT02145234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986089
Study: NCT00217425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Intravenously, either as a bolus injection or as a continuous infusion through a central venous line.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Prednisone is taken orally.
Study: NCT02145234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986089
Study: NCT00217425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: IV push using extravasation precautions.
Study: NCT00702858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Blue Citrus
Description: Five 700 mg Capsules three times a day to equal 15 capsules per day for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Five Placebo capsules three times a day to equal 15 capsules per day for 3 months
Study: NCT00904813

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Short-course RT
Description: Preoperative radiotherapy (RT) given 5 times 5 Gray during five consecutive days, preferably Monday - Friday, with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Short-course RT
Description: Preoperative radiotherapy (RT) given 5 times 5 Gray during five consecutive days, preferably Monday - Friday, with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Long-course RT
Description: Preoperative radiotherapy (RT) given 2 Gy in 25 fractions during 5 weeks, total dose 50 Gy with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
Study: NCT00629226

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Once daily, 5 days a week, for up to 8 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Once daily, 5 days a week, for up to 8 weeks
Study: NCT02145234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986089
Study: NCT04415203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation (TAVNS)
Description: Patients in TAVNS group will receive TAVNS and usual care. TAVNS will be performed on Erzhong and Xin (Auricular Acupuncture Point with vagus nerve distribution) for 6 weeks by using the Huato type SDZ-V stimulator; Usual Care: usual medicine treatment for PVCs.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham-TAVNS)
Description: Patients in sham-TAVNS group will receive sham-TAVNS and usual care. Sham-TAVNS will be also performed on Erzhong and Xin (Auricular Acupuncture Point with vegas nerve stimulation) for 6 weeks by using a special Huato type SDZ-V stimulator. We cut the inner electric wire of the stimulator; therefore, there is no current output. Usual Care: usual medicine treatment for PVCs.
Study: NCT02867267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1
Description: Subcutaneous injections of 1.6 mg thymosin alpha 1 every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injections of placebo every 12±2 hours for not more than 7 days depending on the change of the subjects' condition, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
Study: NCT01395732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: 2 tablets of 62.5 mg a day from baseline to week 4, then 2 tablets of 125 mg per day to week 12.
Study: NCT02335307

Intervention type: GENETIC
Intervention: CYP2D6 genotyping
Description: CYP2D6 genotype results and an interpretive report will be placed in the electronic medical record to assist the physician with prescribing medication for pain management.

Intervention type: OTHER
Intervention: Pain assessment questionnaire
Description: A pain assessment questionnaire will be administered at baseline and 3 months.
Study: NCT02335307

Intervention type: OTHER
Intervention: Pain assessment questionnaire
Description: A pain assessment questionnaire will be administered at baseline and 3 months.

Intervention type: OTHER
Intervention: Physician assessment
Description: 20-item survey administered to physicians treating patients enrolled in the study
Study: NCT04507607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide 25 MG
Description: TAF was administered to pregnant women with CHB during pregnancy for mother-to-child interention.Women with chronic hepatitis B who are not pregnant receive TAF for antiviral treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Alafenamide 25 MG
Description: TAF was administered to pregnant women with CHB during pregnancy for mother-to-child interention.Women with chronic hepatitis B who are not pregnant receive TAF for antiviral treatment.
Study: NCT02776111

Intervention type: OTHER
Intervention: Blood Sample
Description: A one time blood sample will be provided.
Study: NCT04148534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocroniom, Non Depolarizing Muscle Relaxant
Description: compare the operating condition of two different levels of muscle relaxation on facial nerve monitoring using transcranial motor evocked potential in CPA surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rocroniom, Non Depolarizing Muscle Relaxant
Description: compare the operating condition of two different levels of muscle relaxation on facial nerve monitoring using transcranial motor evocked potential in CPA surgery
Study: NCT03056677

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: 200mls water will be given prior to a mixed carbohydrate meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal Whey protein
Description: Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified whey protein
Description: Modified whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
Study: NCT02145234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986089
Study: NCT03049761

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Water Flosser
Description: Power interdental cleaner

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: String Floss
Description: Mechanical interdental cleaner

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Toothbrush
Description: ADA standard soft bristle toothbrush
Study: NCT02792231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab subcutaneous injection
Description: Ofatumumab 20 mg prefilled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter
Study: NCT02792231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide-matching placebo capsules
Description: Placebo capsule, matching in appearance to teriflunomide, taken orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide capsule
Description: Teriflunomide 14 mg oral capsule taken once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo of ofatumumab subcutaneous injections
Description: Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter
Study: NCT01572103

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Administration of 4 cups of coffee per day for 1 month

Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: coffee abstinence
Description: total abstinence for both coffee and caffeine containing beverages
Study: NCT02567747

Intervention type: OTHER
Intervention: Data collection
Description: Data will be collected retrospectively for cases identified through RIPS\*/ DANE\*\* from 2008 until 2014 and through PAI\*\*\* from 2009 until 2014. \*Registro Individual de Prestación de Servicios de Salud (RIPS) database (Health Service Provider Individual Registration Database), Columbia. \*\*Departamento Administrativo Nacional de Estadística (DANE) database (The National Administrative Department of Statistics database), Columbia. \*\*\*Programa Ampliado de Immunizaciones (PAI) database (National Immunization Program database), Columbia.
Study: NCT02107183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow (Fisher & Paykel Healthcare)
Description: This device delivers high-flow oxygen through nasal cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi mask
Description: This device delivers low-flow oxygen at predetermined concentrations
Study: NCT01593332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: two 500 mg rituximab infusions 2 weeks apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: two 500 mg rituximab infusions 2 weeks apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 500mg,two times with two weeks interval

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 500mg,two times with two weeks interval
Study: NCT04073186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE® OASYS with Transitions™
Description: JJVC Marketed Contact Lens
Study: NCT02461667

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SRP plus Placebo Gel
Description: After SRP, placebo gel was delivered subgingivally into the pocket

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRP plus Alendronate gel
Description: Alendronate (ALN) After SRP, ALN gel was delivered subgingivally into the pocket

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRP plus Metformin gel
Description: Metformin (MF) After SRP, MF gel was delivered subgingivally into the pocket